Trastuzumab deruxtecan in - HER2-expressing gynecologic cancers from DESTINY-PanTumor02 - antitumor activity, safety, and exploratory biomarker analyses
Favorite
Share
More Options
20

Open in WPS to view all 20 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
